Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
18 April 2024 | Story Andre Damons | Photo Charl Devenish
Dr Osayande Evbuomwan
Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine at the University of the Free State (UFS), received the first clinical PhD in nuclear medicine completed at the UFS at the April graduation ceremonies.

Dr Osayande Evbuomwan, Senior Lecturer and Medical Specialist in the Department of Nuclear Medicine, Faculty of Health Sciences, at the University of the Free State (UFS), graduated with the first clinical PhD in nuclear medicine completed at the UFS.

He graduated on Thursday (18 April 2024) at the university’s autumn graduation ceremonies when the Faculty of Health Sciences conferred degrees on its graduation class of 2024.

Dr Evbuomwan, the man behind his department using Lutetium 177 PSMA (Lu-177 PSMA) therapy and now Actinium 225 PSMA therapy to treatment metastatic castrate resistant prostate cancer (MCRPC) – an advanced stage prostate cancer, said his PhD is about using a special radiopharmaceutical called Technetium 99m ECDG to detect active disease in the joints of patients with rheumatoid arthritis (RA).

More opportunities for similar degrees

This research has won him the Society of Nuclear Medicine and Molecular Imaging (SNMMI) International Best Abstract Award for South Africa during last year’s SNMMI 2023 Annual Meeting in the US.

“I am very grateful, and at the same time, proud about this achievement (his PhD). This qualification will definitely give more opportunities for further similar degrees at the department. So yes, I feel very happy and fulfilled.

“Rheumatoid arthritis is a debilitating disease with associated morbidity that can lead to serious joint deformity and destruction. The need for an investigation with a very high diagnostic accuracy in detecting active disease is needed, especially in the detection of subclinical disease. Few prior studies in the literature had shown promising results with Tc 99m ECDG imaging in this regard. So, we decided to conduct a proper prospective study to test this hypothesis,” says Dr Evbuomwan.

This research, he explains, was also aimed at finding out if the new nuclear medicine radiopharmaceutical for the identification of active disease in patients with rheumatoid arthritis can also offer prognostic information. This aspect of the study concluded that this particular radiopharmaceutical (Tc – 99m ECDG) is highly sensitive in identifying synovitis (inflammation of the membrane that protects joints) and is capable of offering prognostic information in patients with rheumatoid arthritis.

This was the first prospective study to assess the prognostic value of this radiopharmaceutical in patients with rheumatoid arthritis, Dr Evbuomwan says.

Researching theranostics in the future

According to him, he had a smooth journey to completing his PhD – something he contributes to support from the fantastic team of three supervisors, the assistant who prepared the radiopharmaceutical, the rheumatology department, the radiographers and nurses at the Department of Nuclear Medicine, and most importantly, his wife and two daughters.

His passion for research, growth and the practice of nuclear medicine were his major motivators on this journey.

Dr Evbuomwan is currently looking at the possibility of starting research on theranostics. The only stumbling block for now, he says, is that the department still does not have a PET/CT camera, as this is very vital in today’s nuclear medicine practice. However, together with the Free State Department of Health, they are working hard to secure one.

“I now want to focus on nuclear medicine therapy and its promotion. This includes both imaging and treatment (theranostics) of certain cancers, most especially prostate cancer, neuroendocrine neoplasms, thyroid cancers and the neuroectodermal tumours. I also want to focus on being involved with the training of more registrars at the department of nuclear medicine and increasing the awareness of nuclear medicine amongst colleagues in the Free State,” says Dr Evbuomwan about his future plans. 

News Archive

Nanotechnology breakthrough at UFS
2010-08-19

 Ph.D students, Chantel Swart and Ntsoaki Leeuw


Scientists at the University of the Free State (UFS) made an important breakthrough in the use of nanotechnology in medical and biological research. The UFS team’s research has been accepted for publication by the internationally accredited Canadian Journal of Microbiology.

The UFS study dissected yeast cells exposed to over-used cooking oil by peeling microscopically thin layers off the yeast cells through the use of nanotechnology.

The yeast cells were enlarged thousands of times to study what was going on inside the cells, whilst at the same time establishing the chemical elements the cells are composed of. This was done by making microscopically small surgical incisions into the cell walls.

This groundbreaking research opens up a host of new uses for nanotechnology, as it was the first study ever in which biological cells were surgically manipulated and at the same time elemental analysis performed through nanotechnology. According to Prof. Lodewyk Kock, head of the Division Lipid Biotechnology at the UFS, the study has far reaching implications for biological and medical research.

The research was the result of collaboration between the Department of Microbial, Biochemical and Food Biotechnology, the Department of Physics (under the leadership of Prof. Hendrik Swart) and the Centre for Microscopy (under the leadership of Prof.Pieter van Wyk).

Two Ph.D. students, Chantel Swart and Ntsoaki Leeuw, overseen by professors Kock and Van Wyk, managed to successfully prepare yeast that was exposed to over-used cooking oil (used for deep frying of food) for this first ever method of nanotechnological research.

According to Prof. Kock, a single yeast cell is approximately 5 micrometres long. “A micrometre is one millionth of a metre – in laymen’s terms, even less than the diameter of a single hair – and completely invisible to the human eye.”

Through the use of nanotechnology, the chemical composition of the surface of the yeast cells could be established by making a surgical incision into the surface. The cells could be peeled off in layers of approximately three (3) nanometres at a time to establish the effect of the oil on the yeast cell’s composition. A nanometre is one thousandth of a micrometre.

Each cell was enlarged by between 40 000 and 50 000 times. This was done by using the Department of Physics’ PHI700 Scanning Auger Nanoprobe linked to a Scanning Electron Microscope and Argon-etching. Under the guidance of Prof. Swart, Mss. Swart en Leeuw could dissect the surfaces of yeast cells exposed to over-used cooking oil. 

The study noted wart like outgrowths - some only a few nanometres in diameter – on the cell surfaces. Research concluded that these outgrowths were caused by the oil. The exposure to the oil also drastically hampered the growth of the yeast cells. (See figure 1)  

Researchers worldwide have warned about the over-usage of cooking oil for deep frying of food, as it can be linked to the cause of diseases like cancer. The over-usage of cooking oil in the preparation of food is therefore strictly regulated by laws worldwide.

The UFS-research doesn’t only show that over-used cooking oil is harmful to micro-organisms like yeast, but also suggests how nanotechnology can be used in biological and medical research on, amongst others, cancer cells.

 

Figure 1. Yeast cells exposed to over-used cooking oil. Wart like protuberances/ outgrowths (WP) is clearly visible on the surfaces of the elongated yeast cells. With the use of nanotechnology, it is possible to peel off the warts – some with a diameter of only a few nanometres – in layers only a few nanometres thick. At the same time, the 3D-structure of the warts as well as its chemical composition can be established.  

Media Release
Issued by: Mangaliso Radebe
Assistant Director: Media Liaison
Tel: 051 401 2828
Cell: 078 460 3320
E-mail: radebemt@ufs.ac.za  
18 August 2010
 

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept